Labcorp Holdings Inc. (LH) recently announced the completion of its acquisition of select assets of BioReference Health — a wholly-owned subsidiary of OPKO Health, Inc. (OPK). The transaction is aimed at providing customers with greater access to Labcorp's comprehensive, high-quality laboratory services, scientific expertise and expanded testing capabilities in key regions across the United States. Likely Trend of LH Stock Following the News Following the announcement, shares of Labcorp rose 2.1% to $225.76 ...

BURLINGTON, N.C., Sept. 16, 2024 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH) (Labcorp) announced today that its wholly owned subsidiary, Laboratory Corporation of America Holdings (LCAH), has priced its offering of $2,000,000,000 in senior notes (the Offering). The Offering consists of three tranches: $650,000,000 aggregate principal amount of 4.350% Senior Notes due 2030 (the 2030 Notes), $500,000,000 aggregate principal amount of 4.550% Senior Notes due 2032 (the 2032 Notes) and $850,000,000 aggregate ...

Enhances Labcorp's laboratory services network and expands access to its clinical services BURLINGTON, N.C. and MIAMI, Sept. 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today the completion of Labcorp's acquisition of select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. The transaction is expected to provide ...

Labcorp Holdings, Inc. (LH) has been benefiting from the solid execution of its strategic priorities. Investments in targeted high-growth areas are expected to continue the momentum. The company faces headwinds from macroeconomic uncertainties and growing foreign exchange issues. The stock carries a Zacks Rank #3 (Hold) currently. Factors Driving LH Stock As part of its expansion efforts, Labcorp is focusing more on key growth areas such as oncology, women's health, autoimmune disease and neurology. The com ...

Labcorp (LH) has announced a strategic collaboration with Ballad Health to provide outreach laboratory services across the Appalachian Highlands region. Under the agreement, the company will acquire select operating assets of Ballad Health's outreach lab services, which, combined with their ongoing partnership, aim to enhance patient care, expand access to advanced testing and improve efficiency for the health system and its patients. The companies expect to close the transaction in December 2024, subject t ...

Laboratory Corporation of America Holdings (LH) , or Labcorp, is poised for growth in the upcoming quarters due to its series of strategic acquisitions and partnerships. The company is nearing its targeted savings for the Launchpad business process improvement initiative by the end of 2024. Additionally, its strong emphasis on high-growth sectors like oncology, women's health and neurology paves the way for substantial market gains. Meanwhile, unfavorable solvency and the adverse impacts of macroeconomic ch ...

Labcorp (LH) has been benefiting from the solid execution of its strategic priorities. Investment in targeted high-growth areas should continue to drive the momentum. The company faces headwinds from macroeconomic uncertainties and currency translations. The stock carries a Zacks Rank #3 (Hold) currently. As part of its expansion efforts, Labcorp is focusing more on key growth areas such as oncology, women's health, autoimmune disease and neurology. The company's ability to develop, license and ultimately s ...

Extends Labcorp's leadership in genetic testing solutions for oncology and select rare diseases BURLINGTON, N.C., Aug. 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the completion of its acquisition of select assets of Invitae (OTC:NVTAQ), a leading medical genetics company. Together, Labcorp and Invitae will support patients, clinicians and pharmaceutical partners across the continuum of care, including therapy development, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number 1-11353 LABCORP HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 99-2588107 (State or other jurisdict ...

Labcorp Holdings Inc LH reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates on Thursday. Laboratory Corp reported second-quarter 2024 adjusted EPS of $3.94, up from $3.42 a year ago, beating the consensus of $3.78. Sales increased 6.2% year-over-year to $3.22 billion, beating the consensus of $3.19 billion. Diagnostics Laboratories revenue for the quarter was $2.52 billion, an increase of 7.9%. Biopharma Laboratory Services revenue increased 1. ...